Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
Condition: Erectile Dysfunction
MeSH terms: Erectile Dysfunction
Intervention: placebo; avanafil; avanafil
Intervention description: 30 minutes orally prior to initiation of sexual activity; 30 minutes orally prior to initiation of sexual activity; 30 minutes orally prior to initiation of sexual activity
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 390.0
Sex: Male
Minimum age: 18 Years
Healthy volunteers: No
Keywords: ED; Erectile Dysfunction; Dysfunction; Diabetic; Erectile

Summary:

      This study is being conducted to compare the safety and efficacy of 2 doses of avanafil to
      placebo in diabetic men with mild to severe erectile dysfunction.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male subjects, age ≥ 18 years;

          -  Minimum 6 month history of mild to severe erectile dysfunction;

          -  Have documented diabetes (type 1 or type 2);

          -  Subject is in a monogamous, heterosexual relationship for at least 3 months;

          -  Subject agrees to make at least 4 attempts at intercourse per month;

          -  Subject is willing and able to provide informed consent.

        Exclusion Criteria:

          -  Allergy or hypersensitivity to PDE5 inhibitors;

          -  History of dose-limiting AEs during therapy with a PDE5 inhibitor or hx of consistent
             treatment failure with other PDE5 inhibitors for therapy of ED;

          -  Current or expected use of organic nitrates at any time during the study;

          -  Previous or current antiandrogen therapy;

          -  Use of prescription or over-the-counter drugs known to inhibit the activity of CYP3A4
             at any time during the study;

          -  Androgen replacement therapy that has not been stable for at least 3 month;

          -  Initiation or change in dose of any alpha-blocker within 14 days prior to
             randomization;

          -  ED as a result of spinal cord injury or radical prostatectomy;

          -  Untreated hypogonadism or low serum total testosterone

          -  History of or predisposition to priapism;

          -  Any penile implant;

          -  Elevated PSA, other evidence of prostate cancer, or previous radical prostatectomy;

          -  History of any malignancy (except basal cell carcinoma or squamous cell carcinoma of
             the skin successfully treated by curative excision);

          -  Uncontrolled diabetes;

          -  Uncontrolled hypertension;

          -  Hypotension;

          -  Orthostatic hypotension;

          -  Significant cardiovascular disease;

          -  Abnormal ECG;

          -  Hepatic or renal impairment;

          -  Positive STD screen;

          -  Clinically evident penile lesions, abrasions, or anatomical deformities;

          -  Urinary tract or bladder infection;

          -  Use of any treatment for erectile dysfunction other than study drug at any time during
             the study;

          -  Participation in another investigational study within 30 days of screening or at any
             time during this study;

          -  Previous participation in any other investigational study of avanafil;

          -  History or current drug, alcohol, or substance abuse;

          -  Any history of bipolar disorder or psychosis, greater than one lifetime episode of
             major depression, current depression of moderate or greater severity or antidepressant
             use that has not been stable for at least 3 months;

          -  Partners who are < 18 years of age, who are nursing, who are known to be pregnant at
             screening, who wish to become pregnant during the study period, who have any
             gynecologic problems or major medical conditions that would limit participation in
             sexual intercourse;

          -  Evidence of any other condition by history, physical examination, or laboratory
             studies that, in the opinion of the investigator, would contraindicate the
             administration of study medication, affect compliance, interfere with study
             evaluations, limit study participation, contraindicate sexual activity, or confound
             the interpretation of study results.